Abstract

Perrigo Co PLC is scheduled to report its quarterly results on August 5, 2026 Pre-Market, with investors focused on revenue, margins, and EPS trends after recent leadership changes and reaffirmed full-year guidance.

Market Forecast

Based on current-quarter projections, Perrigo Co PLC is expected to deliver approximately 1.01 billion US dollars in revenue, implying a 6.40% year-over-year decline, with forecast EPS around 0.34 and EBIT of 101.30 million US dollars; available forecasts imply a year-over-year decline of 42.30% for EPS and 27.90% for EBIT. There is no formal quantitative forecast for gross profit margin or net profit margin in the current-quarter projections; the market tone is cautious, emphasizing the recent leadership transition and ongoing normalization of operational throughput.

The main business is expected to remain anchored by Self-Care offerings, where pricing discipline and order pattern normalization are likely to shape top-line cadence and mix, while the company continues to balance promotional intensity and supply-chain execution against retail inventory dynamics and private-label demand. The most promising near-term segment remains Infant Formula, which generated 89.70 million US dollars last quarter and is positioned to benefit from gradual capacity normalization and product availability improvements; year-over-year segment growth data is not disclosed in the available information.

Last Quarter Review

In the previous quarter, Perrigo Co PLC reported revenue of 969.20 million US dollars (down 7.16% year-over-year), a gross profit margin of 33.58%, GAAP net profit attributable to the parent company of -399.00 million US dollars, a net profit margin of -41.13%, and adjusted EPS of 0.43 (down 28.33% year-over-year). A key highlight was an earnings outperformance versus expectations, with adjusted EPS of 0.43 beating a 0.31 estimate by 0.12, offset by a top-line miss versus a 1.03 billion US dollars revenue estimate by 61.86 million US dollars, underscoring a mixed revenue/EPS spread supported by cost and mix factors.

By business line, Self-Care contributed 543.30 million US dollars, Specialty Care 207.00 million US dollars, Infant Formula 89.70 million US dollars, and Other 129.20 million US dollars, with Self-Care representing just over half of the sales mix; while segment-level growth rates were not disclosed, the mix indicates the company’s earnings leverage continues to be most sensitive to Self-Care volumes and pricing.

Current Quarter Outlook

Core Self-Care execution and margin trajectory

Self-Care remains the largest driver of quarterly earnings variability given its scale and mix. With forecast company revenue at roughly 1.01 billion US dollars and EPS at 0.34 for the quarter, the pacing of Self-Care volumes and the balance between private-label penetration and branded price/mix are likely to determine how close results land to expectations. Absent a formal gross-margin target for the quarter, last quarter’s 33.58% gross profit margin provides a baseline; any improvement this quarter depends on procurement savings, input cost normalization, and the extent of promotional investment required to support shelf velocity at retail partners. Operating leverage will also hinge on how efficiently the company aligns manufacturing throughput with demand after the production headwinds referenced for the current fiscal year.

The last reported quarter showed a revenue miss but an EPS beat, implying cost discipline and mix offsetting weaker top-line. For the near term, that pattern can repeat if Self-Care maintains healthy SKU-level profitability, even if revenue growth remains constrained. Channel inventory rationalization and the cadence of retailer orders could introduce lumpiness; however, a steadier order flow should support consistent factory utilization and reduce overhead under-absorption. A tighter spread between list pricing and promotion-adjusted net realized price would aid margin stability. Monitoring freight and packaging costs is important, as these line items can move faster than procurement contracts and influence gross margin in a short period. If Self-Care holds above half of total revenue near the prior-quarter level and mix shifts toward higher-margin categories, the EBIT trajectory can track close to the 101.30 million US dollars forecast despite revenue headwinds.

Infant Formula recovery and operational normalization

Infant Formula, at 89.70 million US dollars last quarter, is the company’s most promising near-term recovery lever, given the potential to recapture volumes as capacity constraints ease and product availability improves. The company has acknowledged that prior-year production headwinds are weighing on the current year’s earnings profile by roughly 0.60 per share; the key question for this quarter is how much of that drag can be mitigated by higher throughput, efficiency gains, and smoother changeover schedules. A more predictable production rhythm should drive better absorption and reduce cost-per-unit, feeding through to margins even if top-line growth remains measured.

From a demand standpoint, steady shelf presence and improved fill rates tend to restore brand and private-label momentum in the category. That said, forecasting precision remains limited without formal segment guidance, so investors will look for qualitative signals: improved case fill metrics, reduced backorders, and consistent weekly run-rates at plants. If these operational indicators track positively, segment profitability can improve faster than sales, as fixed-cost dilution recedes. The near-term focus is less on outsized revenue acceleration and more on stabilizing output to protect gross margin. With company-wide revenue projected to decline year-over-year this quarter, a solid performance from Infant Formula would mitigate top-line pressure and could cushion any downside surprises in other categories.

Stock price sensitivities this quarter

The stock’s near-term performance is likely to be most sensitive to three factors: leadership stability and its signaling effect on strategy execution, the translation of reaffirmed full-year guidance into quarterly cadence, and the depth of the year-over-year declines embedded in consensus for this quarter. Management recently appointed an interim CEO while retaining its full-year 2026 outlook, which includes all-in adjusted EPS of 2.00 to 2.30 and a modest net sales decline; how management communicates the bridge from a softer quarter (revenue down 6.40% year-over-year) to the full-year plan will influence investor confidence. Credible interim milestones—such as throughput increases in formula, cost take-outs, and operating expense control—can narrow the perceived execution gap.

The balance between revenue pressure and earnings resilience is another pivot point. With forecast EPS at approximately 0.34, a repeat of last quarter’s pattern—beating EPS despite a revenue miss—would underscore ongoing cost controls and better mix. However, if promotional intensity or input costs pressure gross margin below last quarter’s 33.58% baseline, it would be harder to sustain the earnings trajectory implied by the full-year range. Investors will parse commentary on procurement, logistics, and labor efficiency to assess whether any adverse variance is transitory or structural.

Finally, one-off items continue to matter for GAAP optics. The prior GAAP net loss of -399.00 million US dollars and net margin of -41.13% reflect non-recurring effects that can overshadow underlying adjusted progress. If this quarter’s GAAP-to-adjusted bridge is modest and clean, the market may refocus on run-rate profitability. Conversely, any new exceptional charges could reignite concern around predictability. Clarity on the magnitude and timing of any remaining non-cash items would help reduce valuation uncertainty.

Analyst Opinions

Across recent commentary, the balance of views trends cautious. Counting directional signals in the available coverage—an EPS beat paired with a revenue miss (supportive), reaffirmed full-year guidance amid a leadership transition (mixed to cautious), prior production headwinds expected to reduce this year’s EPS by about 0.60 (cautious), and recent impairment-related optics (cautious)—the ratio of bullish to bearish opinions skews roughly 25% to 75%. The majority view highlights execution risk and near-term revenue pressure even as cost controls support adjusted profitability.

A widely referenced benchmark indicates that consensus, as compiled by FactSet, centers around quarterly EPS near 0.34 on approximately 1.01 billion US dollars of revenue, consistent with a 6.40% year-over-year decline in sales. Analysts emphasizing caution cite three factors. First, full-year guidance re-affirmation is constructive but requires sequential improvement in the back half; without crisp evidence of formula throughput gains and steadier Self-Care order patterns, the pathway is less certain. Second, leadership changes can temporarily slow commercial and operational decision-making, raising the execution bar for the next several months. Third, the expected EPS burden from prior production challenges suggests limited buffer for unforeseen margin headwinds this quarter.

Supportive elements in the minority view revolve around cost discipline and the prospect of cleaner GAAP-to-adjusted reconciliation. The prior quarter’s adjusted EPS outperformance versus expectations, despite a revenue shortfall, reflects underlying expense control and mix management. If similar dynamics persist—steady procurement costs, no material escalation in promotions, and continued operating expense restraint—analysts see room for a modest EPS beat even if revenue lands near the 1.01 billion US dollars mark. Some also point to the reaffirmed full-year 2026 range (adjusted EPS of 2.00 to 2.30) as an anchor that can steady sentiment if this quarter’s results show tangible progress on the operational milestones that underpin that outlook.

The majority, however, remains guarded and will look for evidence that the company can close the gap between a down quarter and full-year goals without relying on atypical one-offs. Based on the available previews and financial benchmarks, the key swing variables that could shift opinions toward a more constructive stance are: a stable or improving gross profit margin relative to last quarter’s 33.58%, clearer signs of Infant Formula production normalization translating into better absorption, and confirmation that Self-Care mix can support margin even as top-line trends remain soft. A delivery against these markers would likely recalibrate expectations and compress the bearish skew; absent that, the cautious majority view is likely to persist into the next update.